Hypersensitivity and Infusion-Site Adverse Events with Intravenous Fosaprepitant after Anthracycline-Containing Chemotherapy: A Retrospective Study

201817 citationsJournal Articlehybrid Open Access

Authors

Robert B. Geller · Heron Therapeutics (United States)

Neil J. Clendeninn · Heron Therapeutics (United States)

Thomas Ottoboni · Heron Therapeutics (United States)

Abstract

Fosaprepitant is associated with a significant ISAE/HSR rate following anthracycline-containing chemotherapy via peripheral line. Polysorbate 80-free intravenous neurokinin-1 receptor antagonist may provide a safer chemotherapy-induced nausea and vomiting prophylaxis option.

Topics & Keywords

Nausea and vomiting management Chemotherapy-related skin toxicity Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Future Oncology

Volume 15, Issue 3, pp. 297-303

DOI: 10.2217/fon-2018-0662

Field-Weighted Citation Impact: 0.93